Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic discovers ’new pathway’ against pancreatic cancer

15.03.2005


Pancreatic cancer kills 30,000 Americans every year. Not only is there no cure, but there are no effective treatments. That may change if a new finding by Mayo Clinic researchers continues to show promise. In the March 15 issue of the journal Cancer Research, (http://cancerres.aacrjournals.org/future/65.6.shtml) investigators describe discovering a key molecule that controls the growth, spread and survival of pancreatic cancer cells. This is a critical first step toward developing new and better treatments for patients with pancreatic cancer.



"This is a very exciting -- and surprising -- finding," says Daniel Billadeau, Ph.D., lead author of the report. To identify new target molecules with potentially therapeutic impact for a cancer for which there is currently no real useful treatment is incredibly important.

"Based on the literature, you would predict the opposite of what we found. But in fact, we determined that we can decrease a known regulator of cancer cell survival -- in effect, turn this regulator off -- and when we do, the pancreatic cancer cells undergo apoptosis (commit cell suicide) and die."


Significance of the Research

With this finding, a new path is cleared for researchers to target these key molecular players with new small molecule inhibitors to block their action, effectively turning off molecules that promote pancreatic cancer growth.

The finding may be applied to make pancreatic cells more sensitive to gemcitabine, the sole drug available for treating pancreatic cancer.

This discovery may lead to new drug development strategies for other cancers. Additional research will tell whether these same actors play a similar role in the spread of other cancer types.

The Key Finding

The Mayo Clinic researchers discovered a previously unrecognized role in pancreatic cancer for the GSK-3 Beta molecule. They determined that GSK-3 Beta is vital to pancreatic cancer cell survival and growth through its effects on a well-known gene regulator called NF Kappa B (pronounced "en-ef-kappa-bee").

The NF Kappa B protein is well known to researchers as a transcription factor that regulates many genes. In cancer cells, NF Kappa B regulates genes involved in cancer cell survival, proliferation and blood vessel formation (angiogenesis). NF Kappa B is hyperactive in many human cancers including pancreatic. The Mayo Clinic study shows that in pancreatic cancer, the activity of NF Kappa B is regulated by GSK-3 Beta. Researchers determined this by showing that if they could decrease GSK-3 Beta protein or inactivate it using small molecular inhibitors, they could likewise decrease NF Kappa B -- and deprive the pancreatic cancer cells of a means to grow and survive.

Notably, in pancreatic cancer, NF Kappa B activity is high -- which can cause resistance to chemotherapy drugs used to treat the disease. This new information suggests a potential means of treating pancreatic cancer by a two-pronged attack of administering the gemcitabine in combination with a drug to block GSK-3 Beta.

Nearly all die within five years of diagnosis

Despite recent advances in understanding how cancers work at the molecular level, pancreatic cancer lacks an effective treatment. Approximately 30,000 Americans are diagnosed with pancreatic cancer annually, and the disease kills the same number each year. Ninety percent of these cancers are pancreatic ductular adenocarcinoma, the fourth leading cause of cancer deaths in the United States. Pancreatic cancer patients have one of the poorest prognoses -- the five-year survival rate is 3 percent. Because pancreatic cancer is aggressive, spreads rapidly and few treatment options are available, researchers welcome any promising leads for improving diagnosis and therapy.

Bob Nellis | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Life Sciences:

nachricht Modern genetic sequencing tools give clearer picture of how corals are related
17.08.2017 | University of Washington

nachricht The irresistible fragrance of dying vinegar flies
16.08.2017 | Max-Planck-Institut für chemische Ökologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>